| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.05 M USD | -8.83 M USD | -8.53 M USD | -11.55 M USD | -9.35 M USD | -7.25 M USD | -6.45 M USD | -5.31 M USD | -4.86 M USD | -786000 USD | -30.68 M USD | -27.35 M USD |
| Depreciation & Amortization | 47000 USD | 91000 USD | 106000 USD | 102000 USD | 76000 USD | 68000 USD | 84000 USD | 54000 USD | 21000 USD | 10000 USD | 1.13 M USD | 1.31 M USD |
| Stock-Based Compensation | 1.06 M USD | 1.35 M USD | 1.39 M USD | 1.75 M USD | 1.39 M USD | 1.94 M USD | 1.10 M USD | 1.40 M USD | 479000 USD | 676000 USD | 4.24 M USD | 2.03 M USD |
| Capital Expenditures | 60000 USD | 25000 USD | 33000 USD | 84000 USD | 69000 USD | 91000 USD | 216000 USD | 223000 USD | 58000 USD | 25000 USD | 1.05 M USD | 903943 USD |
| Cash Flow from Investing | -72.38 M USD | 1.54 M USD | 1.97 M USD | -3.84 M USD | 3.20 M USD | -2.77 M USD | -2.45 M USD | -223000 USD | -85000 USD | -25000 USD | -885280 USD | -425622 USD |
| Cash Flow from Financing | 86.24 M USD | 7.94 M USD | 6.56 M USD | 4.32 M USD | — | -3.38 M USD | 36.77 M USD | -18000 USD | 13.02 M USD | 3.08 M USD | 18.71 M USD | 22.20 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -13.11 M USD | -8.85 M USD | -8.57 M USD | -11.63 M USD | -9.42 M USD | -7.34 M USD | -6.67 M USD | -5.53 M USD | -4.91 M USD | -811000 USD | -31.73 M USD | -28.26 M USD |
Microbot Medical Inc. is a cutting-edge medical device company focused on enhancing healthcare through innovative technologies. The company's primary function is to develop micro-robotic medical solutions, with an emphasis on improving minimally invasive surgeries and medical procedures. This focus addresses the growing demand for precision, efficacy, and less invasive treatment options within the healthcare sector. Notably, Microbot Medical Inc. is pioneering advancements in the field of robotic technology to facilitate endoluminal procedures, which involve navigation through natural body lumens such as blood vessels or the gastrointestinal tract. With its headquarters in Massachusetts, USA, the company plays a significant role in the medical device market, contributing to the ongoing evolution of surgical practices and patient care. As healthcare providers increasingly prioritize technological advancements to reduce recovery times and enhance procedural accuracy, Microbot Medical Inc.'s innovations become crucial to achieving these goals. The company's commitment to micro-robotics positions it as a transformative entity within the healthcare technology landscape.